Cargando…

Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia

BACKGROUND: Methotrexate (MTX) eradicates leukemic cells by disrupting de novo nucleotide biosynthesis and DNA replication, resulting in cell death. Since its introduction in 1947, MTX-containing chemotherapeutic regimens have proven instrumental in achieving curative effects in acute lymphoblastic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wojtuszkiewicz, Anna, Peters, Godefridus J., van Woerden, Nicole L., Dubbelman, Boas, Escherich, Gabriele, Schmiegelow, Kjeld, Sonneveld, Edwin, Pieters, Rob, van de Ven, Peter M., Jansen, Gerrit, Assaraf, Yehuda G., Kaspers, Gertjan J. L., Cloos, Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455979/ https://www.ncbi.nlm.nih.gov/pubmed/26022503 http://dx.doi.org/10.1186/s13045-015-0158-9

Ejemplares similares

Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation
por: Sciarrillo, Rocco, et al.
Publicado: (2020)

Association of altered folylpolyglutamate synthetase pre-mRNA splicing with methotrexate unresponsiveness in early rheumatoid arthritis
por: Muller, Ittai B, et al.
Publicado: (2020)

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
por: Niewerth, Denise, et al.
Publicado: (2014)

Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells
por: Jansen, Gerrit, et al.
Publicado: (2023)

Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia: Clinical Facts and Fiction
por: Schmiegelow, Kjeld, et al.
Publicado: (2014)

P329: HIGH IMMUNOPROTEASOME ACTIVITY AS NOVEL INDICATOR FOR SENSITIVITY TO BORTEZOMIB-CONTAINING CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM CHILDREN’S ONCOLOGY GROUP TRIAL AALL1231
por: Roeten, Margot, et al.
Publicado: (2023)

Methotrexate Provokes Disparate Folate Metabolism Gene Expression and Alternative Splicing in Ex Vivo Monocytes and GM-CSF- and M-CSF-Polarized Macrophages
por: Muller, Ittai B., et al.
Publicado: (2023)

(Immuno)proteasomes as therapeutic target in acute leukemia
por: Cloos, Jacqueline, et al.
Publicado: (2017)

Epidemiology of Therapy-Related Myeloid Neoplasms After Treatment for Pediatric Acute Lymphoblastic Leukemia in the Nordic Countries.
por: Schmiegelow, Kjeld
Publicado: (2011)

SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
por: van der Werf, Inge, et al.
Publicado: (2021)

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia
por: Østergaard, Anna, et al.
Publicado: (2023)

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
por: Sciarrillo, Rocco, et al.
Publicado: (2018)

Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia
por: Cucchi, David G.J., et al.
Publicado: (2020)

Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia
por: Nersting, Jacob, et al.
Publicado: (2011)

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide
por: Oerlemans, Ruud, et al.
Publicado: (2018)

Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia
por: Oosterom, Natanja, et al.
Publicado: (2018)

Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia
por: Sari, Nur Melani, et al.
Publicado: (2021)

Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors
por: Franke, Niels E., et al.
Publicado: (2016)

Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions
por: Thastrup, Maria, et al.
Publicado: (2022)

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
por: Niewerth, Denise, et al.
Publicado: (2016)

Maternal diabetes and risk of childhood acute lymphoblastic leukaemia in the offspring
por: Søegaard, Signe Holst, et al.
Publicado: (2018)

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
por: Roeten, Margot S.F., et al.
Publicado: (2021)

Flow Cytometric Detection of Malignant Blasts in Cerebrospinal Fluid: A Biomarker of Central Nervous System Involvement in Childhood Acute Lymphoblastic Leukemia
por: Thastrup, Maria, et al.
Publicado: (2022)

Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia
por: Driehuis, E., et al.
Publicado: (2020)

Computational comparison of common event-based differential splicing tools: practical considerations for laboratory researchers
por: Muller, Ittai B., et al.
Publicado: (2021)

MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia
por: Verboon, Lonneke J., et al.
Publicado: (2016)

Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations
por: Toksvang, Linea N., et al.
Publicado: (2022)

Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia
por: Oosterom, Natanja, et al.
Publicado: (2019)

Correction: Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia
por: Driehuis, E., et al.
Publicado: (2020)

Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion
por: Baruchel, André, et al.
Publicado: (2020)

P366: ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?
por: Stutterheim, Janine, et al.
Publicado: (2023)

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients
por: Sassen, Sebastiaan D.T., et al.
Publicado: (2017)

Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia
por: Mogensen, Pernille Rudebeck, et al.
Publicado: (2020)

Health-related quality of life and utility scores in short-term survivors of pediatric acute lymphoblastic leukemia
por: van Litsenburg, Raphaële R. L., et al.
Publicado: (2012)

Pharmacokinetic–pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia
por: Gebhard, Anna, et al.
Publicado: (2023)

The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia
por: Oosterom, N., et al.
Publicado: (2020)

Impaired sleep affects quality of life in children during maintenance treatment for acute lymphoblastic leukemia: an exploratory study
por: van Litsenburg, Raphaële RL, et al.
Publicado: (2011)

Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations
por: Antić, Željko, et al.
Publicado: (2020)

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors
por: Verbrugge, Sue Ellen, et al.
Publicado: (2013)

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients
por: Scheijen, Blanca, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_psh56u9nm7nt0m3uutfppmlqj9